Skip to Main Content

Paper Details

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
34
2023
AKT, Advanced NSCLC, CDKN2A, KEAP1, KRASG12C, KRASG12C-mutant, KRASG12C-mutant NSCLC, KRASG12Ci, MTOR, NSCLC, PI3K, RAS gene, SMARCA4, non-small cell lung cancer, patient, patients, tumor, tumor suppressor genes, tumors
Author NameAffiliation
James K HicksH. Lee Moffitt Cancer Center
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg
Subba R DigumarthyMassachusetts General Hospital
Jianjun ZhangThe University of Texas MD Anderson Cancer Center
Collin M BlakelyUniversity of California San Francisco
Amy L CummingsUniversity of California Los Angeles
Amy L CummingsUniversity of California Los Angeles
Leylah M Drusbosky
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2